Wormhole Capital

Wormhole Capital serves as the dedicated investment vehicle for the family office of Vivek Garipalli, the visionary co-founder and former CEO of Clover Health. Garipalli's entrepreneurial success, particularly with Clover Health's public listing via SPAC in 2021 which at one point valued the company at over $7 billion, underpins the significant capital and strategic insight available to Wormhole Capital. The firm operates with a flexible, stage-agnostic investment mandate, deploying capital across the entire spectrum from early-stage seed rounds to mature growth equity opportunities. This broad approach allows Wormhole Capital to support promising ventures at various points in their development lifecycle.

The investment strategy of Wormhole Capital is heavily concentrated on the healthcare technology and services sectors, a clear reflection of Garipalli's deep industry expertise and successful track record. Its portfolio showcases a strong inclination towards innovative companies that are disrupting traditional healthcare models. Notable investments include participation in significant funding rounds for leading digital health platforms such as Carbon Health, Devoted Health, and Ro. For instance, Wormhole Capital was involved in Carbon Health's $300 million Series D round and Ro's $500 million Series C, demonstrating its capacity to engage in substantial capital raises alongside prominent institutional investors.

As a family office, Wormhole Capital typically seeks to be a long-term partner, often co-investing with established venture capital firms and other strategic investors. While specific check sizes are not publicly disclosed, their participation in multi-hundred-million-dollar rounds suggests a robust capacity for significant capital deployment. Based on their historical investments spanning from seed to late-stage growth, Wormhole Capital's typical first check size likely ranges from approximately $1,000,000 for early-stage opportunities to upwards of $25,000,000 for more mature, growth-oriented companies. This flexibility allows them to tailor their investment to the specific needs and stage of each portfolio company, solidifying their reputation as a strategic and well-capitalized investor in the evolving healthcare landscape.